Skip to main content
SpringerLink
Log in
Book cover

Management of Cardiac Arrhythmias pp 165–193Cite as

Pharmacologic Management of Atrial Fibrillation and Flutter

  • Chapter
  • First Online:

  • 1705 Accesses

Part of the book series: Contemporary Cardiology ((CONCARD))

Abstract

Atrial fibrillation is the most commonly encountered arrhythmia requiring therapy and is associated with significant morbidity, a reduced quality of life, an increased risk for mortality, a significant likelihood of hospitalization, an increased risk for stroke and systemic embolism, and significant costs. Both rate control and rhythm control have been shown to improve quality of life. Neither as a strategy has been proven to reduce mortality versus the other; however, in some series the attainment and maintenance of sinus rhythm has had superior outcomes if risks from therapy are not encountered (especially those of amiodarone). In patients with markers of an increased risk for stroke, anticoagulation with warfarin is essential. In all patients, rate control is also necessary so as to reduce both symptoms and the risk for a tachycardia-induced cardiomyopathy. The choice of rhythm control strategy must be individualized based on patient characteristics. This chapter will review the considerations necessary for choosing appropriate pharmacologic therapies as well as the therapeutic agents themselves.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Miyasaka Y, Barnes ME, Gersh BJ et al (2006) Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114(2):119–125

    PubMed  Google Scholar 

  2. Luderitz B, Jung W (2000) Quality of life in patients with atrial fibrillation. Arch Intern Med 160(12):1749–1757

    PubMed  CAS  Google Scholar 

  3. Benjamin EJ, Wolf PA, D’Agostino RB et al (1998) Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation 98(10):946–592

    Google Scholar 

  4. Carlsson J, Miketic S, Windeler J et al (2003) Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the strategies of treatment of atrial fibrillation (STAF) study. J Am Coll Cardiol 41(10):1690–1696

    PubMed  Google Scholar 

  5. Opolski G, Torbicki A, Kosior DA et al (2004) Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the polish how to treat chronic atrial fibrillation (HOT CAFE) Study. Chest 126(2):476–486

    Google Scholar 

  6. Van Gelder IC, Hagens VE, Bosker HA et al (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347(23):1834–1840

    PubMed  Google Scholar 

  7. Wyse DG, Waldo AL, DiMarco JP et al (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347(23):1825–1833

    PubMed  CAS  Google Scholar 

  8. Corley SD, Epstein AE, DiMarco JP et al (2004) Relationships between sinus rhythm, treatment, and survival in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Circulation 109(12):1509–1513

    PubMed  Google Scholar 

  9. Hohnloser SH, Crijns HJ, van Eickels M et al (2009) Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360(7):668–678

    PubMed  CAS  Google Scholar 

  10. Reiffel J (2009) Current assignment of rate vs rhythm control for atrial fibrillation by US cardiologists: the AFFECTS registry. Heart Rhythm 6(5):S104–S105

    Google Scholar 

  11. Fuster V, Ryden LE, Cannom DS et al (2006) ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European heart rhythm association and the heart rhythm society. Circulation 114(7):e257–e354

    PubMed  Google Scholar 

  12. Reant P, Lafitte S, Jais P et al (2005) Reverse remodeling of the left cardiac chambers after catheter ablation after 1 year in a series of patients with isolated atrial fibrillation. Circulation 112(19):2896–2903

    PubMed  Google Scholar 

  13. Alboni P, Botto GL, Baldi N et al (2004) Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med 351(23):2384–2391

    PubMed  CAS  Google Scholar 

  14. O’Neill MD, Jais P, Hocini M et al (2007) Catheter ablation for atrial fibrillation. Circulation 116(13):1515–1523

    PubMed  Google Scholar 

  15. Oral H, Pappone C, Chugh A et al (2006) Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 354(9):934–941

    PubMed  CAS  Google Scholar 

  16. Hsu LF, Jais P, Sanders P et al (2004) Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 351(23):2373–2383

    PubMed  CAS  Google Scholar 

  17. Roy D, Talajic M, Nattel S et al (2008) Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358(25):2667–2677

    PubMed  CAS  Google Scholar 

  18. Hohnloser SH, Kuck KH, Lilienthal J (2000) Rhythm or rate control in atrial fibrillation – pharmacological intervention in atrial fibrillation (PIAF): a randomised trial. Lancet 356(9244):1789–1794

    PubMed  CAS  Google Scholar 

  19. Pedersen OD, Bagger H, Keller N et al (2001) Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 104(3):292–296

    PubMed  CAS  Google Scholar 

  20. Deedwania PC, Singh BN, Ellenbogen K et al (1998) Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The department of veterans affairs CHF-STAT investigators. Circulation 98(23):2574–2579

    PubMed  CAS  Google Scholar 

  21. Vidaillet H, Greenlee RT (2005) Rate control versus rhythm control. Curr Opin Cardiol 20(1): 15–20

    PubMed  Google Scholar 

  22. Dorian P, Jung W, Newman D et al (2000) The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol 36(4):1303–1309

    PubMed  CAS  Google Scholar 

  23. Gronefeld GC, Lilienthal J, Kuck KH et al (2003) Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. Eur Heart J 24(15):1430–1436

    PubMed  Google Scholar 

  24. Hagens VE, Ranchor AV, Van Sonderen E et al (2004) Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the rate control versus electrical cardioversion (RACE) study. J Am Coll Cardiol 43(2):241–247

    PubMed  Google Scholar 

  25. Jenkins LS, Brodsky M, Schron E et al (2005) Quality of life in atrial fibrillation: the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Am Heart J 149(1):112–120

    PubMed  Google Scholar 

  26. Singh SN, Tang XC, Singh BN et al (2006) Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a veterans affairs cooperative studies program substudy. J Am Coll Cardiol 48(4):721–730

    PubMed  Google Scholar 

  27. Chung MK, Shemanski L, Sherman DG et al (2005) Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) functional status substudy. J Am Coll Cardiol 46(10):1891–1899

    PubMed  Google Scholar 

  28. Lin CS, Pan CH (2008) Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci 65(10):1489–1508

    PubMed  CAS  Google Scholar 

  29. Dittrich HC, Erickson JS, Schneiderman T et al (1989) Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am J Cardiol 63(3):193–197

    CAS  Google Scholar 

  30. Hagens VE, Crijns HJ, Van Veldhuisen DJ et al (2005) Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte control versus electrical cardioversion (RACE) study. Am Heart J 149(6):1106–1111

    PubMed  Google Scholar 

  31. Efremidis M, Sideris A, Xydonas S et al (2008) Ablation of atrial fibrillation in patients with heart failure: reversal of atrial and ventricular remodelling. Hellenic J Cardiol 49(1):19–25

    PubMed  Google Scholar 

  32. Raitt MH, Kusumoto W, Giraud G et al (2004) Reversal of electrical remodeling after cardioversion of persistent atrial fibrillation. J Cardiovasc Electrophysiol 15(5):507–512

    PubMed  Google Scholar 

  33. Gage BF, Waterman AD, Shannon W et al (2001) Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA 285(22):2864–2870

    PubMed  CAS  Google Scholar 

  34. Stroke Prevention in Atrial Fibrillation Investigators (1994) Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet 343(8899):687–691

    Google Scholar 

  35. Hart RG, Halperin JL (1999) Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 131(9):688–695

    PubMed  CAS  Google Scholar 

  36. Manning WJ, Silverman DI, Katz SE et al (1994) Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol 23(7):1535–1540

    PubMed  CAS  Google Scholar 

  37. Page RL, Wilkinson WE, Clair WK et al (1994) Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 89(1):224–227

    PubMed  CAS  Google Scholar 

  38. Cai H, Li Z, Goette A et al (2002) Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation 106(22):2854–2858

    PubMed  CAS  Google Scholar 

  39. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA et al (2006) Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 166(7):719–728

    PubMed  CAS  Google Scholar 

  40. Fetsch T, Bauer P, Engberding R et al (2004) Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 25(16):1385–1394

    PubMed  Google Scholar 

  41. Volgman AS, Carberry PA, Stambler B et al (1998) Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol 31(6):1414–1419

    PubMed  CAS  Google Scholar 

  42. Kirpizidis C, Stavrati A, Geleris P et al (2001) Safety and effectiveness of oral quinidine in cardioversion of persistent atrial fibrillation. J Cardiol 38(6):351–354

    PubMed  CAS  Google Scholar 

  43. Flaker GC, Blackshear JL, McBride R et al (1992) Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The stroke prevention in atrial fibrillation investigators. J Am Coll Cardiol 20(3):527–532

    PubMed  CAS  Google Scholar 

  44. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA et al (2007) Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev (4):CD005049

    Google Scholar 

  45. Stiell IG, Clement CM, Symington C et al (2007) Emergency department use of intravenous procainamide for patients with acute atrial fibrillation or flutter. Acad Emerg Med 14(12):1158–1164

    PubMed  Google Scholar 

  46. Karlson BW, Torstensson I, Abjorn C et al (1988) Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. Eur Heart J 9(3):284–290

    PubMed  CAS  Google Scholar 

  47. Meinertz T, Lip GY, Lombardi F et al (2002) Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European rythmol/rytmonorm atrial fibrillation trial (ERAFT) study). Am J Cardiol 90(12):1300–1306

    PubMed  CAS  Google Scholar 

  48. Pritchett EL, Page RL, Carlson M et al (2003) Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol 92(8):941–946

    PubMed  CAS  Google Scholar 

  49. Stroobandt R, Stiels B, Hoebrechts R (1997) Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone atrial fibrillation trial investigators. Am J Cardiol 79(4):418–423

    PubMed  CAS  Google Scholar 

  50. Anderson JL, Gilbert EM, Alpert BL et al (1989) Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide supraventricular tachycardia study group. Circulation 80(6):1557–1570

    PubMed  CAS  Google Scholar 

  51. Chimienti M, Cullen MT Jr, Casadei G (1996) Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the flecainide and propafenone Italian study investigators. Am J Cardiol 77(3):60A–75A

    PubMed  CAS  Google Scholar 

  52. Capucci A, Boriani G, Rubino I et al (1994) A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol 43(3):305–313

    PubMed  CAS  Google Scholar 

  53. Boriani G, Capucci A, Lenzi T et al (1995) Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration. Chest 108(2):355–358

    PubMed  CAS  Google Scholar 

  54. Aliot E, Denjoy I (1996) Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The flecainide AF French study group. Am J Cardiol 77(3):66A–71A

    PubMed  CAS  Google Scholar 

  55. Pritchett EL, Kowey P, Connolly S et al (2006) Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. Am Heart J 151(5):1043–1049

    PubMed  CAS  Google Scholar 

  56. Ruskin JN (1989) The cardiac arrhythmia suppression trial (CAST). N Engl J Med 321(6):386–388

    PubMed  CAS  Google Scholar 

  57. The Cardiac Arrhythmia Suppression Trial II Investigators (1992) Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327(4):227–233

    Google Scholar 

  58. Workman AJ, Kane KA, Russell JA et al (2003) Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evidence of pharmacological remodelling. Cardiovasc Res 58(3):518–525

    PubMed  CAS  Google Scholar 

  59. Psaty BM, Manolio TA, Kuller LH et al (1997) Incidence of and risk factors for atrial fibrillation in older adults. Circulation 96(7):2455–2461

    PubMed  CAS  Google Scholar 

  60. Kuhlkamp V, Schirdewan A, Stangl K et al (2000) Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 36(1):139–146

    PubMed  CAS  Google Scholar 

  61. Steeds RP, Birchall AS, Smith M et al (1999) An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart 82(2):170–175

    PubMed  CAS  Google Scholar 

  62. Plewan A, Lehmann G, Ndrepepa G et al (2001) Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. Eur Heart J 22(16):1504–1510

    PubMed  CAS  Google Scholar 

  63. Crystal E, Connolly SJ, Sleik K et al (2002) Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation 106(1):75–80

    PubMed  Google Scholar 

  64. Connolly SJ, Cybulsky I, Lamy A et al (2003) Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: the beta-blocker length of stay (BLOS) study. Am Heart J145(2):226–232

    PubMed  CAS  Google Scholar 

  65. Halonen J, Hakala T, Auvinen T et al (2006) Intravenous administration of metoprolol is more effective than oral administration in the prevention of atrial fibrillation after cardiac surgery. Circulation 114(1 Suppl):I1–I4

    Google Scholar 

  66. Tsuboi J, Kawazoe K, Izumoto H et al (2008) Postoperative treatment with carvedilol, a beta-adrenergic blocker, prevents paroxysmal atrial fibrillation after coronary artery bypass grafting. Circ J 72(4):588–591

    PubMed  CAS  Google Scholar 

  67. Acikel S, Bozbas H, Gultekin B et al (2008) Comparison of the efficacy of metoprolol and carvedilol for preventing atrial fibrillation after coronary bypass surgery. Int J Cardiol 126(1):108–113

    PubMed  Google Scholar 

  68. Platia EV, Michelson EL, Porterfield JK et al (1989) Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol 63(13):925–929

    PubMed  CAS  Google Scholar 

  69. Wolbrette DL (2003) Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol 91(6A):39D–44D

    PubMed  CAS  Google Scholar 

  70. Shantsila E, Watson T, Lip GY (2007) Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias. Europace 9(Suppl 4):iv37–iv44

    Google Scholar 

  71. Gowda RM, Khan IA, Wilbur SL et al (2004) Torsade de pointes: the clinical considerations. Int J Cardiol 96(1):1–6

    PubMed  Google Scholar 

  72. Saluja D, Guyotte J, Reiffel J (2008) An improved QT correction method for use in atrial fibrillation and a comparison with the assessment of QT in sinus rhythm. J Atrial Fib 1(1):1–11

    Google Scholar 

  73. Roy D, Talajic M, Dorian P et al (2000) Amiodarone to prevent recurrence of atrial fibrillation. Canadian trial of atrial fibrillation investigators. N Engl J Med 342(13):913–920

    PubMed  CAS  Google Scholar 

  74. Singh BN, Singh SN, Reda DJ et al (2005) Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352(18):1861–1872

    PubMed  CAS  Google Scholar 

  75. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug (2003). J Am Coll Cardiol 42(1):20–29

    Google Scholar 

  76. Kochiadakis GE, Igoumenidis NE, Hamilos MI et al (2004) Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs propafenone, both in low doses. Chest 125(2):377–383

    PubMed  CAS  Google Scholar 

  77. Kochiadakis GE, Igoumenidis NE, Marketou ME et al (2000) Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart 84(3):251–257

    PubMed  CAS  Google Scholar 

  78. Chevalier P, Durand-Dubief A, Burri H et al (2003) Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 41 (2):255–262

    PubMed  CAS  Google Scholar 

  79. Letelier LM, Udol K, Ena J et al (2003) Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis. Arch Intern Med 4163(7):777–785

    Google Scholar 

  80. Kochiadakis GE, Igoumenidis NE, Parthenakis FI et al (1999) Amiodarone versus propafenone for conversion of chronic atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol 33(4):966–971

    PubMed  CAS  Google Scholar 

  81. Galperin J, Elizari MV, Chiale PA et al (2001) Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial. J Cardiovasc Pharmacol Ther 6(4):341–350

    PubMed  CAS  Google Scholar 

  82. Capucci A, Villani GQ, Aschieri D et al (2000) Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J 21(1):66–73

    PubMed  CAS  Google Scholar 

  83. Anderson JL, Prystowsky EN (1999) Sotalol: an important new antiarrhythmic. Am Heart J 137(3):388–409

    PubMed  CAS  Google Scholar 

  84. Hohnloser SH, van de Loo A, Baedeker F (1995) Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 26(4):852–858

    PubMed  CAS  Google Scholar 

  85. Halinen MO, Huttunen M, Paakkinen S et al (1995) Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the sotalol-digoxin-quinidine trial). Am J Cardiol 76(7):495–498

    PubMed  CAS  Google Scholar 

  86. Singh S, Saini RK, DiMarco J et al (1991) Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. The sotalol study group. Am J Cardiol 68(11):1227–1230

    PubMed  CAS  Google Scholar 

  87. Benditt DG, Williams JH, Jin J et al (1999) Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-sotalol atrial fibrillation/flutter study group. Am J Cardiol 84(3): 270–277

    PubMed  CAS  Google Scholar 

  88. Wanless RS, Anderson K, Joy M et al (1997) Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J 133(4):441–446

    PubMed  CAS  Google Scholar 

  89. Reimold SC, Cantillon CO, Friedman PL et al (1993) Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 71(7):558–563

    PubMed  CAS  Google Scholar 

  90. MacNeil DJ, Davies RO, Deitchman D (1993) Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol 72(4):44A–50A

    PubMed  CAS  Google Scholar 

  91. Lehmann MH, Hardy S, Archibald D et al (1996) Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 94(10):2535–2541

    PubMed  CAS  Google Scholar 

  92. Pacifico A, Hohnloser SH, Williams JH et al (1999) Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-sotalol implantable cardioverter-defibrillator study group. N Engl J Med 340(24):1855–1862

    PubMed  CAS  Google Scholar 

  93. Falk RH, Pollak A, Singh SN et al (1997) Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous dofetilide investigators. J Am Coll Cardiol 29(2):385–390

    PubMed  CAS  Google Scholar 

  94. Ferguson JJ (1999) Meeting highlights. Highlights of the 71st scientific sessions of the American heart association. Circulation 99(19):2486–2491

    PubMed  CAS  Google Scholar 

  95. Singh S, Zoble RG, Yellen L et al (2000) Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 102(19):2385–2390

    PubMed  CAS  Google Scholar 

  96. Pritchett EL, Wilkinson WE (1999) Effect of dofetilide on survival in patients with supraventricular arrhythmias. Am Heart J 138(5 Pt 1):994–997

    PubMed  CAS  Google Scholar 

  97. Lee KS (1992) Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na+ current in guinea pig ventricular cells. J Pharmacol Exp Ther 262(1):99–108

    PubMed  CAS  Google Scholar 

  98. Buchanan LV, Kabell G, Brunden MN et al (1993) Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol 22(4):540–549

    PubMed  CAS  Google Scholar 

  99. Stambler BS, Wood MA, Ellenbogen KA et al (1996) Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide repeat dose study investigators. Circulation 94(7):1613–1621

    PubMed  CAS  Google Scholar 

  100. Abi-Mansour P, Carberry PA, McCowan RJ et al (1998) Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Study investigators. Am Heart J 136(4 Pt 1):632–642

    PubMed  CAS  Google Scholar 

  101. Tercius AJ, Kluger J, Coleman CI et al (2007) Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation or flutter. Pacing Clin Electrophysiol 30(11):1331–1335

    PubMed  Google Scholar 

  102. Ellenbogen KA, Stambler BS, Wood MA et al (1996) Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 28(1):130–136

    PubMed  CAS  Google Scholar 

  103. Gowda RM, Khan IA, Punukollu G et al (2004) Female preponderance in ibutilide-induced torsade de pointes. Int J Cardiol 95(2–3):219–222

    PubMed  Google Scholar 

  104. Tieleman RG, De Langen C, Van Gelder IC et al (1997) Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation 95(7):1945–1953

    PubMed  CAS  Google Scholar 

  105. Daoud EG, Knight BP, Weiss R et al (1997) Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation 96(5):1542–1550

    PubMed  CAS  Google Scholar 

  106. Moriguchi M, Niwano S, Yoshizawa N et al (2003) Verapamil suppresses the inhomogeneity of electrical remodeling in a canine long-term rapid atrial stimulation model. Pacing Clin Electrophysiol 26(11):2072–2082

    PubMed  Google Scholar 

  107. Shenasa M, Kus T, Fromer M et al (1988) Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation. Am J Cardiol 62(7):403–407

    PubMed  CAS  Google Scholar 

  108. Amar D, Roistacher N, Rusch VW et al (2000) Effects of diltiazem prophylaxis on the incidence and clinical outcome of atrial arrhythmias after thoracic surgery. J Thorac Cardiovasc Surg 120(4):790–798

    PubMed  CAS  Google Scholar 

  109. Villani GQ, Piepoli MF, Terracciano C et al (2000) Effects of diltiazem pretreatment on direct-current cardioversion in patients with persistent atrial fibrillation: a single-blind, randomized, controlled study. Am Heart J 140(3):e12

    PubMed  CAS  Google Scholar 

  110. Singh BN, Connolly SJ, Crijns HJ et al (2007) Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 357(10):987–999

    PubMed  CAS  Google Scholar 

  111. Kober L, Torp-Pedersen C, McMurray JJ et al (2008) Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 358(25):2678–2687

    PubMed  Google Scholar 

  112. Roy D, Pratt CM, Torp-Pedersen C et al (2008) Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 117(12):1518–1525

    PubMed  CAS  Google Scholar 

  113. Pritchett EL, Page RL, Connolly SJ et al (2000) Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide supraventricular arrhythmia program 3 (SVA-3) investigators. J Am Coll Cardiol 36(3):794–802

    PubMed  CAS  Google Scholar 

  114. Camm AJ, Pratt CM, Schwartz PJ et al (2004) Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 109(8):990–996

    PubMed  Google Scholar 

  115. Kerr CR, Connolly SJ, Kowey P et al (2006) Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. Am J Cardiol 98(2):215–218

    PubMed  CAS  Google Scholar 

  116. Morrow JP, Reiffel JA (2009) Drug therapy for atrial fibrillation: what will its role be in the era of increasing use of catheter ablation? Pacing Clin Electrophysiol 32(1):108–118

    PubMed  Google Scholar 

  117. Morrow JP, Cannon CP, Reiffel JA (2007) New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: what are our therapies likely to be by 2010 and beyond? Am Heart J 154(5):824–829

    PubMed  CAS  Google Scholar 

  118. Segal JB, McNamara RL, Miller MR et al (2000) The evidence regarding the drugs used for ventricular rate control. J Fam Pract 49(1):47–59

    PubMed  CAS  Google Scholar 

  119. Olshansky B, Rosenfeld LE, Warner AL et al (2004) The atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 43(7):1201–1208

    PubMed  Google Scholar 

  120. Packer M, Bristow MR, Cohn JN et al (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US carvedilol heart failure study group. N Engl J Med 334(21):1349–1355

    PubMed  CAS  Google Scholar 

  121. Agarwal AK, Venugopalan P (2001) Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy. Eur J Heart Fail 3(4):437–440

    PubMed  CAS  Google Scholar 

  122. Goldstein RE, Boccuzzi SJ, Cruess D et al (1991) Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The adverse experience committee; and the multicenter diltiazem postinfarction research group. Circulation 83(1):52–60

    PubMed  CAS  Google Scholar 

  123. Reiffel JA (1992) Improved rate control in atrial fibrillation. Am Heart J 123(4 Pt 1):1094–1098

    PubMed  CAS  Google Scholar 

  124. Clemo HF, Wood MA, Gilligan DM et al (1998) Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 81(5):594–598

    PubMed  CAS  Google Scholar 

  125. Davy JM, Herold M, Hoglund C et al (2008) Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the efficacy and safety of dRonedArone for the control of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 156(3):527 e1–e9

    PubMed  Google Scholar 

  126. Tamariz LJ, Bass EB (2004) Pharmacological rate control of atrial fibrillation. Cardiol Clin 22(1):35–45

    PubMed  Google Scholar 

  127. Lundstrom T, Ryden L (1990) Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil. J Am Coll Cardiol 16(1):86–90

    PubMed  CAS  Google Scholar 

  128. Delle Karth G, Geppert A, Neunteufl T et al (2001) Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med 29(6):1149–1153

    PubMed  CAS  Google Scholar 

  129. Jordaens L, Trouerbach J, Calle P et al (1997) Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. Eur Heart J 18(4):643–648

    PubMed  CAS  Google Scholar 

  130. Falk RH, Knowlton AA, Bernard SA et al (1987) Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial. Ann Intern Med 106(4):503–506

    PubMed  CAS  Google Scholar 

  131. Julian DG, Camm AJ, Frangin G et al (1997) Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European myocardial infarct amiodarone trial investigators. Lancet 349(9053):667–674

    PubMed  CAS  Google Scholar 

  132. Cairns JA, Connolly SJ, Roberts R et al (1997) Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian amiodarone myocardial infarction arrhythmia trial investigators. Lancet 349(9053):675–682

    PubMed  CAS  Google Scholar 

  133. Julian DG, Prescott RJ, Jackson FS et al (1982) Controlled trial of sotalol for one year after myocardial infarction. Lancet 1(8282):1142–1147

    PubMed  CAS  Google Scholar 

  134. Packer M, Coats AJ, Fowler MB et al (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344(22):1651–1658

    PubMed  CAS  Google Scholar 

  135. Dargie HJ (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357(9266):1385–1390

    PubMed  CAS  Google Scholar 

  136. Massie BM, Fisher SG, Radford M et al (1996) Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT investigators. Circulation 93(12):2128–2134

    PubMed  CAS  Google Scholar 

  137. Ben-David J, Zipes DP, Ayers GM et al (1992) Canine left ventricular hypertrophy predisposes to ventricular tachycardia induction by phase 2 early afterdepolarizations after administration of BAY K 8644. J Am Coll Cardiol 20(7):1576–1584

    PubMed  CAS  Google Scholar 

  138. Prystowsky EN (2000) Management of atrial fibrillation: therapeutic options and clinical decisions. Am J Cardiol 85(10A):3D–11D

    PubMed  CAS  Google Scholar 

  139. Hart RG, Benavente O, McBride R et al (1999) Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131(7):492–501

    PubMed  CAS  Google Scholar 

  140. Hart RG, Pearce LA, McBride R et al (1999) Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The stroke prevention in atrial fibrillation (SPAF) investigators. Stroke 30(6):1223–1229

    PubMed  CAS  Google Scholar 

  141. EAFT (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European atrial fibrillation trial) study group. Lancet 342(8882):1255–1262

    Google Scholar 

  142. Fang MC, Singer DE, Chang Y et al (2005) Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the Anticoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 112(12):1687–1691

    PubMed  Google Scholar 

  143. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation (1994) Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154(13):1449–1457

    Google Scholar 

  144. Moulton AW, Singer DE, Haas JS (1991) Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study. Am J Med 91(2):156–161

    PubMed  CAS  Google Scholar 

  145. Boysen G, Nyboe J, Appleyard M et al (1988) Stroke incidence and risk factors for stroke in Copenhagen, Denmark. Stroke 19(11):1345–1353

    PubMed  CAS  Google Scholar 

  146. Kopecky SL, Gersh BJ, McGoon MD et al (1987) The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 317(11):669–674

    PubMed  CAS  Google Scholar 

  147. Capucci A, Santini M, Padeletti L et al (2005) Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol 46(10):1913–1920

    PubMed  Google Scholar 

  148. Hart RG, Pearce LA, Rothbart RM et al (2000) Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke prevention in atrial fibrillation investigators. J Am Coll Cardiol 35(1):183–187

    PubMed  CAS  Google Scholar 

  149. Hohnloser SH, Pajitnev D, Pogue J et al (2007) Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 50(22):2156–2161

    PubMed  CAS  Google Scholar 

  150. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation (1990) The Boston area anticoagulation trial for atrial fibrillation investigators. N Engl J Med 323(22):1505–1511

    Google Scholar 

  151. Stroke Prevention in Atrial Fibrillation Study (1991) Final results. Circulation 84(2):527–539

    Google Scholar 

  152. Petersen P, Boysen G, Godtfredsen J et al (1989) Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1(8631):175–179

    PubMed  CAS  Google Scholar 

  153. Connolly SJ, Laupacis A, Gent M et al (1991) Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 18(2):349–355

    PubMed  CAS  Google Scholar 

  154. Ezekowitz MD, Bridgers SL, James KE et al (1992) Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators. N Engl J Med 327(20):1406–1412

    PubMed  CAS  Google Scholar 

  155. Ezekowitz MD, Levine JA (1999) Preventing stroke in patients with atrial fibrillation. JAMA 281(19):1830–1835

    PubMed  CAS  Google Scholar 

  156. Hylek EM, Skates SJ, Sheehan MA et al (1996) An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335(8):540–546

    PubMed  CAS  Google Scholar 

  157. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia (1995) The European atrial fibrillation trial study group. N Engl J Med 333(1):5–10

    Google Scholar 

  158. The efficacy of aspirin in patients with atrial fibrillation (1997) Analysis of pooled data from 3 randomized trials. The atrial fibrillation investigators. Arch Intern Med 157(11):1237–1240

    Google Scholar 

  159. Stroke Prevention in Atrial Fibrillation III randomised clinical trial (1996) Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation. Lancet 348(9028):633–638

    Google Scholar 

  160. Connolly S, Pogue J, Hart R et al (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367(9526):1903–1912

    PubMed  CAS  Google Scholar 

  161. Connolly SJ, Pogue J, Hart RG et al (2009) Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 360(20):2066–2078

    PubMed  Google Scholar 

  162. van Walraven C, Hart RG, Singer DE et al (2002) Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 288(19):2441–2448

    PubMed  Google Scholar 

  163. Hart RG, Benavente O, Pearce LA (1999) Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis 9(4):215–217

    PubMed  CAS  Google Scholar 

  164. Shireman TI, Howard PA, Kresowik TF et al (2004) Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 35(10):2362–2367

    PubMed  CAS  Google Scholar 

  165. Surawicz B, Knilans T (2001) Atrial flutter and atrial fibrillation. In: Chou’s electrocardiography in clinical practice, 5th edn. Saunders, Philadelphia, PA, p 345

    Google Scholar 

  166. Waldo AL (2003) Inter-relationships between atrial flutter and atrial fibrillation. Pacing Clin Electrophysiol 26(7 Pt 2):1583–1596

    PubMed  Google Scholar 

  167. Biblo LA, Yuan Z, Quan KJ et al (2001) Risk of stroke in patients with atrial flutter. Am J Cardiol 87(3):346–349, A9

    PubMed  CAS  Google Scholar 

  168. Andrew P, Montenero AS (2007) Atrial flutter: a focus on treatment options for a common supraventricular tachyarrhythmia. J Cardiovasc Med (Hagerstown) 8(8):558–567

    Google Scholar 

  169. Ghali WA, Wasil BI, Brant R et al (2005) Atrial flutter and the risk of thromboembolism: a systematic review and meta-analysis. Am J Med 118(2):101–107

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiac Care Unit, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, USA

    Deepak Saluja MD

  2. Columbia University Medical Center, New York, NY, USA

    Kathleen Hickey (R.N. AND DOCTOR OF NURSING)

  3. Department of Medicine, Columbia University Medical Center, New York, NY, USA

    James A. Reiffel MD

Authors
  1. Deepak Saluja MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathleen Hickey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James A. Reiffel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Main Line Health Heart Center, 100 Lancaster Ave, Wynnewood, 19096, Pennsylvania, USA

    Gan-Xin Yan

  2. Main Line Health Heart Center, 100 Lancaster Ave, Wynnewood, 19096, Pennsylvania, USA

    Peter R. Kowey

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Saluja, D., Hickey, K., Reiffel, J.A. (2011). Pharmacologic Management of Atrial Fibrillation and Flutter. In: Yan, GX., Kowey, P. (eds) Management of Cardiac Arrhythmias. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-161-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-161-5_8

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-160-8

  • Online ISBN: 978-1-60761-161-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation